Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1

Conditions

Lymphoma, T-Cell, Peripheral 4Melanoma 3Neoplasms 2Lymphoproliferative Disorders 2Lymphoma 2Fallopian Tube Neoplasms 2Carcinoma, Ovarian Epithelial 2Pancreatic Neoplasms 1Neoplasms by Histologic Type 1Neoplasm Metastasis 1Multiple Myeloma 1Lymphoma, Non-Hodgkin 1Lymphoma, Follicular 1Lymphoma, B-Cell 1Lymphatic Diseases 1Leukemia-Lymphoma, Adult T-Cell 1Leukemia, Myeloid, Acute 1Breast Neoplasms, Male 1Breast Neoplasms 1

Interventions

mogamulizumab 3Cyclophosphamide 3Lenalidomide 2Alemtuzumab 2ruxolitinib 1peginterferon alfa-2b 1fludarabine phosphate 1fludarabine 1etoposide phosphate 1denileukin diftitox 1belinostat 1Zidovudine 1Vincristine 1Raltegravir Potassium 1Prednisone 1Oxaliplatin 1Introns 1Interleukin-15 1Gemcitabine 1Etoposide 1Doxorubicin 1Dexamethasone 1Daclizumab 1Cytarabine 1Cisplatin 1Calcium Dobesilate 1Bortezomib 1B3(Fv)-PE38KDEL recombinant immunotoxin 110-propargyl-10-deazaaminopterin 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Has results × Leukemia-Lymphoma, Adult T-Cell × denileukin diftitox × Clear all
NCT00117845 2019-11-19

Phase II Study of the Efficacy and Toxicity of Ontak(Registered Trademark) (Denileukin Diftitox) in the Therapy of Adult T-Cell Leukemia

National Institutes of Health Clinical Center (CC)

Phase 2 Terminated
17 enrolled 9 charts
LymphoidOther hematologic neoplasm

Lymphoproliferative Disorders, Leukemia-Lymphoma, Adult T-Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡